Rangeley Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Rangeley Capital’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-75,953	Closed	-$1.64M	–	140
2025 Q4	$1.64M	Buy	+75,953	New	+$1.47M	1.36%	25

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Rangeley Capital's AVDL Position: Q1 2026 in Review

Rangeley Capital sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 75,953 shares — an estimated $1.64M sold.

Rangeley Capital first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $1.64M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Rangeley Capital reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Rangeley Capital sold 75,953 Avadel Pharmaceuticals shares in Q1 2026, an estimated $1.64M.
Rangeley Capital first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Rangeley Capital's Avadel Pharmaceuticals position peaked at $1.64M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.